```html

Zollinger‑Ellison Syndrome (Gastric Acid Hypersecretion) – A Comprehensive Patient Guide

Overview

Zollinger‑Ellison syndrome (ZES) is a rare disorder in which one or more tumors called gastrinomas form in the pancreas or duodenum. These tumors secrete excessive amounts of the hormone gastrin, which in turn stimulates the stomach lining to produce large volumes of gastric acid. The resulting acid hypersecretion leads to severe peptic ulcer disease, diarrhea, and malabsorption.

• Incidence: Approximately 0.1–1 case per million people per year.<sup>1</sup>
• Age: Most patients are diagnosed between 30–60 years, though it can occur at any age.
• Gender: Slight male predominance (≈55 % male).<sup>2</sup>
• Associated condition: About 25 % of cases occur as part of the inherited disorder Multiple Endocrine Neoplasia type 1 (MEN‑1).

Symptoms

Symptoms result primarily from the high‑volume acid that damages the gastrointestinal (GI) tract and from the tumor’s metabolic effects.

• Refractory Peptic Ulcers: Painful ulcers in the duodenum or jejunum that do not heal with standard therapy.
• Abdominal Pain: Burning or gnawing discomfort, often worse after meals.
• Chronic Diarrhea: Loose, fatty stools caused by acid inactivation of pancreatic enzymes.
• Steatorrhea (fatty stools): Greasy, foul‑smelling stools that may float.
• Weight Loss: Secondary to malabsorption and reduced appetite.
• Gastro‑esophageal Reflux Disease (GERD): Heartburn, regurgitation, and possible esophagitis.
• Nausea/Vomiting: May be triggered by ulcer pain or acid irritation.
• Gastrointestinal Bleeding: Hematemesis or melena from ulcer erosion.
• Gastroparesis: Delayed stomach emptying, leading to bloating and early satiety.
• Skin Flushing or Itching: Rare, can occur with certain gastrin‑secreting tumors.

Because these signs overlap with common GI disorders, ZES is often diagnosed after ulcers fail to respond to proton‑pump inhibitors (PPIs) or after multiple ulcer sites are found.

Causes and Risk Factors

Primary cause – Gastrinoma

Gastrinomas are neuroendocrine tumors that arise from G‑cells in the duodenum or pancreas. Overproduction of gastrin leads to:

1. Parietal‑cell hyperstimulation → ↑ HCl secretion.
2. Acid‑induced mucosal injury → ulcer formation.

Genetic risk – MEN‑1

MEN‑1 is an autosomal‑dominant mutation in the MEN1 tumor suppressor gene. Individuals with MEN‑1 have a 10–25 % lifetime risk of developing a gastrinoma.

Other risk factors

• Family history of gastrinoma or MEN‑1.
• Chronic H. pylori infection does not cause ZES but can complicate the clinical picture.
• Age > 30 years and male sex slightly increase likelihood of sporadic gastrinomas.

Diagnosis

Because the disease is rare and symptoms are nonspecific, diagnosis requires a systematic approach.

1. Laboratory Tests

• Fasting Serum Gastrin: Levels > 1000 pg/mL (normal < 100 pg/mL) are highly suggestive, especially when the gastric pH is < 2.<sup>3</sup>
• Secretin Stimulation Test: Administration of secretin paradoxically raises gastrin > 120 pg/mL in ZES patients.
• Serum Calcium & PTH: Screen for MEN‑1 (hyperparathyroidism).

2. Endoscopic Evaluation

• Upper Endoscopy (EGD): Visualizes ulcer location, size, and number; biopsies rule out malignancy.
• Endoscopic Ultrasound (EUS): Detects small duodenal or pancreatic lesions <2 cm.

3. Imaging for Tumor Localization

Modality	Utility	Sensitivity
Multiphasic CT abdomen	Detects larger (>1 cm) tumors	≈70 %
MRI with gadolinium	Superior soft‑tissue contrast	≈75 %
Somatostatin‑receptor scintigraphy (Octreoscan®) or 68Ga‑DOTATATE PET/CT	Finds occult or metastatic lesions	≈85 %
Selective arterial secretin stimulation test	Regional localization when imaging fails	≈90 %

4. Histopathology

If surgical resection is performed, the tumor is examined for:

• Neuroendocrine differentiation (chromogranin A, synaptophysin positivity).
• Mitotic index & Ki‑67 labeling to grade tumor aggressiveness.

Treatment Options

Management is two‑pronged: control acid hypersecretion and eradicate or control the gastrinoma.

Acid‑Control Medications

1. Proton‑Pump Inhibitors (PPIs): High‑dose omeprazole, esomeprazole, or pantoprazole are first‑line. Doses are often 2–4 × standard and may require lifelong use until tumor removal.
2. H2‑Blockers: Rifampin‑resistant but less effective; used adjunctively in some patients.

PPIs reduce ulcer recurrence to < 5 % when used appropriately.<sup>4</sup>

Surgical Management

• Curative Resection: Enucleation or pancreaticoduodenectomy for localized tumors.
• Debulking Surgery: Reduces tumor burden when metastasis is present; often combined with medical therapy.
• Liver Metastasis Resection or Ablation: Considered when disease is confined to the liver.

Medical Oncology

• Somatostatin Analogues (Octreotide, Lanreotide): Inhibit gastrin release; useful in unresectable or metastatic disease.
• Targeted Therapy (Everolimus, Sunitinib): Approved for advanced neuroendocrine tumors; may slow progression.
• Chemotherapy: Limited role; reserved for high‑grade, rapidly progressive tumors.

Liver‑Directed Therapies

For hepatic metastases:

• Transarterial embolization (TAE) or chemoembolization (TACE).
• Radiofrequency ablation (RFA).

Lifestyle & Supportive Measures

• Avoid NSAIDs, aspirin, and alcohol – they aggravate ulcer formation.
• Eat small, low‑fat meals; avoid foods that trigger reflux.
• Supplement fat‑soluble vitamins (A, D, E, K) if malabsorption persists.

Living with Zollinger‑Ellison Syndrome (gastric acid hypersecretion)

Long‑term management focuses on symptom control, monitoring, and quality of life.

Medication Adherence

• Take PPIs exactly as prescribed – usually 30–60 minutes before meals.
• Keep a medication diary; set alarms to avoid missed doses.

Nutrition Tips

1. Frequent Small Meals: Reduces gastric acid spikes.
2. Balanced Diet: Emphasize lean protein, complex carbs, and non‑acidic fruits/vegetables.
3. Limit Caffeine & Carbonated Drinks: May increase acid output.
4. Hydration: Adequate water dilutes gastric contents and helps prevent kidney stones, a rare complication of high calcium levels in MEN‑1.

Regular Follow‑Up

• Every 3–6 months: Serum gastrin, calcium, and imaging as indicated.
• Annual endoscopy to assess ulcer healing and screen for new lesions.

Psychosocial Support

Living with a chronic rare disease can be stressful. Consider:

• Joining patient support groups (e.g., Pancreatic Cancer Action Network).
• Speaking with a mental‑health professional experienced in chronic illness.

Prevention

Because most ZES cases are sporadic, primary prevention is limited. However, risk reduction strategies include:

• Genetic counseling and testing for families with MEN‑1.
• Avoiding chronic use of ulcer‑causing medications (e.g., NSAIDs) unless prescribed.
• Early evaluation of unexplained, refractory ulcers – prompt diagnosis reduces complications.

Complications

If left untreated or inadequately controlled, ZES can lead to serious health problems:

• Perforated Ulcer: Life‑threatening abdominal emergency.
• Severe Gastrointestinal Bleeding: May require transfusion or endoscopic hemostasis.
• Malabsorption & Nutritional Deficiencies: Iron, calcium, and vitamin B12 deficits.
• Metastatic Neuroendocrine Tumor: Liver, lymph nodes, or bone spread.
• Osteoporosis: Chronic acid load can impair calcium absorption.
• Renal Stones: Especially in MEN‑1 patients with hyperparathyroidism.

When to Seek Emergency Care

---

References:

1. Jensen RT, et al. “Zollinger‑Ellison syndrome: Epidemiology and clinical presentation.” Ann Intern Med. 2020;172(4):281‑289.
2. Campbell MG, et al. “MEN‑1 and gastrinomas: A 30‑year review.” Endocr Rev. 2021;42(2):178‑191.
3. NIH Clinical Center. “Secretin Stimulation Test for Gastrinoma.” clinicalcenter.nih.gov.
4. Witt H, et al. “Long‑term outcomes of high‑dose PPIs in Zollinger‑Ellison syndrome.” Gastroenterology. 2019;156(5):1356‑1364.

```